• Víctor J Costela-Ruiz, Lucia Melguizo-Rodríguez, Rebeca Illescas-Montes, Javier Ramos-Torrecillas, Francisco J Manzano-Moreno, Concepción Ruiz, and Elvira De Luna- Bertos.
• Biomedical Group (BIO277). Department of Nursing, Faculty of Health Sciences. University of Granada, Avda. Ilustración 60, 18016. Granada, Spain.
• Int J Med Sci. 2019 Jan 1; 16 (11): 146614721466-1472.

AbstractNon-steroidal anti-inflammatory drugs (NSAIDs), including cyclooxygenase-2 (COX-2)-selective NSAIDs, are associated with adverse effects on bone tissue. These drugs are frequently the treatment of choice but are the least studied with respect to their repercussion on bone. The objective of this study was to determine the effects of celecoxib on cultured human osteoblasts. Human osteoblasts obtained by primary culture from bone samples were treated with celecoxib at doses of 0.75, 2, or 5μM for 24 h. The MTT technique was used to determine the effect on proliferation; flow cytometry to establish the effect on cell cycle, cell viability, and antigenic profile; and real-time polymerase chain reaction to measure the effect on gene expressions of the differentiation markers RUNX2, alkaline phosphatase (ALP), osteocalcin (OSC), and osterix (OSX). Therapeutic doses of celecoxib had no effect on osteoblast cell growth or antigen expression but had a negative impact on the gene expression of RUNX2 and OSC, although there was no significant change in the expression of ALP and OSX. Celecoxib at therapeutic doses has no apparent adverse effects on cultured human osteoblasts and only inhibits the expression of some differentiation markers. These characteristics may place this drug in a preferential position among NSAIDs used for analgesic and anti-inflammatory therapy during bone tissue repair.© The author(s).

34 keywords...

hide…